A 226-base pair fragment (؊4625 to ؊4400 nucleotides) was further localized as the minimal enhancer region, in which deletion of either element A (؊4625 to ؊4581 nucleotides) or element B (؊4418 to ؊4400 nucleotides) resulted in the loss of enhancer activity. Electrophoretic mobility shift assay confirmed that these two elements bind to specific nuclear proteins individually. In the middle region between element A and B, disruption of enhancer integrity also led to a loss of enhancer activity, although two SP1 and three NF-B/c-Rel binding sites did not contribute to enhancer function. These results demonstrate a complex regulation of the human LIFR gene, including alternative promoter usage and tissue-specific elements at the transcription level.
Knockout of the leukemia inhibitory factor receptor (LIFR) gene results in disrupted placental architecture, imbalanced bone development, and losses of functional neurons. We here report the identification of an enhancer in a functional human LIFR gene promoter and alternative promoter usage by this gene. A single transcription start site was identified in placental JEG-3 cells and a genomic clone containing 4876-nucleotide upstream sequences was found to have promoter activity in JEG-3 cells. However, in osteogenic sarcoma U-2 OS cell, Northern blot using a probe of the first exon detected in JEG-3 cells failed to detect LIFR transcripts. 5-Rapid amplification of cDNA ends (RACE) revealed an alternative first exon and a 0.6-kilobase pair (kb) 5-flanking region possessed promoter activity in U-2 OS cells. For the 4.8-kb promoter active in placental cells, a minimal promoter was localized within ؊162 nucleotides. Three regions increased and one inhibited promoter activity. Subcloning of an activation region (؊4876 to ؊3453 nucleotides) into SV40 promoter either upstream or downstream in either orientation to the luciferase reporter resulted in 10 -35-fold luciferase induction, demonstrating the characteristics of an enhancer. Transfections into nine cell lines of different tissue origin indicated that the cloned promoter and enhancer in the 4.8-kb fragment was placental tissuespecific. A 226-base pair fragment (؊4625 to ؊4400 nucleotides) was further localized as the minimal enhancer region, in which deletion of either element A (؊4625 to ؊4581 nucleotides) or element B (؊4418 to ؊4400 nucleotides) resulted in the loss of enhancer activity. Electrophoretic mobility shift assay confirmed that these two elements bind to specific nuclear proteins individually. In the middle region between element A and B, disruption of enhancer integrity also led to a loss of enhancer activity, although two SP1 and three NF-B/c-Rel binding sites did not contribute to enhancer function. These results demonstrate a complex regulation of the human LIFR gene, including alternative promoter usage and tissue-specific elements at the transcription level.
The leukemia inhibitory factor receptor (LIFR) 1 is an integral component of gp130⅐LIFR signaling complex (1) (2) (3) (4) , which participates in signal transduction by members of the interleukin-6 (IL-6) cytokine family, currently including IL-6, leukemia inhibitory factor (LIF), interleukin-11 (IL-11), oncostatin M, ciliary neurotropic factor, and cardiotrophin (1, 5) . Members of this family possess pleiotropic and redundant functions as assessed by in vitro assays and or gene knockout experiments (5) (6) (7) . These include growth promotion and/or activation of hematopoietic, hepatic, osteogenic, and or neuronal cells (1, 2, 8, 9) . On the other hand, these cytokines also exhibit respective specific actions. For example, adult female LIF knockout mice are unable to implant embryos, resulting in infertility (6) , and LIF has also been found to synergize with corticotropin-releasing hormone to regulate pro-opiomelanocortin gene transcription (10 -13); IL-6 appears to be a major mitogenic stimulant in liver regeneration and also a causative agent for postmenopausal osteoporosis (5, 14) ; and cardiotrophin expression is restricted to the heart at an early stage of mouse cardiogenesis (15) . This common gp130⅐LIFR complex may explain some redundant functions of these cytokines, whereas existence of specific receptors for some cytokines and or their tissue-specific distribution and/or density of cytokines and their respective receptors may determine specific distal actions.
A 3.6-kb cDNA clone of the human LIFR was obtained in library screening, which contained an entire coding region of 1097 amino acid residues with a 44-residue signal sequence, a 789-residue extracellular domain, a 26-residue transmembrane domain, and a 238-residue cytoplasmic domain, while identification of the 5Ј-and 3Ј-noncoding regions was incomplete (16) . The murine LIFR cDNA sequence was also reported (16) , and the existence of a soluble murine LIFR was predicted. HLIFR is located on human chromosome 5p12-p13, and analysis of its protein structure shows that it belongs to a hematopoietic cytokine receptor family, which comprises receptors functioning in immune and hematopoietic systems such as IL-2R (␤ and ␥ chains), IL-3R, IL-4R, IL-5R, IL-6R, IL-7R, IL-9R, erythropoietin receptor, granulocyte colony-stimulating factor receptor, granulocyte macrophage colony-stimulating factor (17) (18) (19) , and other receptor proteins for factors that are believed normally to function outside the immune and hematopoietic systems, such as growth hormone, prolactin, ciliary neurotropic factor, and leptin (17, 20, 21) . This hematopoietic cytokine receptor family is characterized by an extracellular (ϳ200 amino acid) portion composed of two folding domains, * This work was supported by National Institutes of Health Grant DK50238. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. usually with four conserved cysteine residues in the N-terminal, and a Trp-Ser-X-Trp-Ser motif in the C-terminal domain (17) , while not possessing recognizable tyrosine kinase domains (18) .
Knockout of the LIFR gene in mice demonstrates that LIFR is essential for animal survival (22, 23) . Pleiotropic defects occurring in these mice (22) include disrupted placental architecture, leading to poor intrauterine nutrition; imbalanced bone development with both reduced bone volume and increased osteoclast numbers resulting in severe perinatal osteopenia; excessive fetal hepatic glycogen storage; and significant losses of neurons including reduced spinal cord and brain stem astrocytes, facial motor, spinal motor, and nucleus ambiguous neurons (23) . Furthermore, these homozygote animals died within 24 h of birth (22, 23) . These findings underlie the critical biological function of the LIFR gene. However, the molecular mechanism of the expression and regulation of this gene is unknown because no LIFR gene promoter has been identified in any species. As a major step to understand LIFR transcriptional regulation, we isolated a human LIFR promoter functional in placental tissue, identified a placenta-specific upstream enhancer, and demonstrated alternative promoter usage by the human LIFR gene.
EXPERIMENTAL PROCEDURES
Cell Culture-A human choriocarcinoma cell line JEG-3 (ATCC HTB-36) was maintained in Dulbecco's modified Eagle's medium, high glucose (Life Technologies, Inc.) supplemented with 10% fetal bovine serum (FBS) (Life Technologies, Inc.), another human choriocarcinoma JAR (ATCC HTB-144) and a human thyroid carcinoma TC1 (gift of Dr. Jerome Hershman) were maintained in RPMI 1640 with 10% FBS. A human osteogenic sarcoma cell line U-2 OS (ATCC HTB-96) was maintained in McCoy's 5A medium (Life Technologies, Inc.) with 10% FBS. A human hepatocellular carcinoma cell line Hep3B (ATCC HB-8064) and a human cervix carcinoma HeLa cell (ATCC CCL-2) were maintained in ␣-minimal essential medium (Life Technologies Inc.) with 10% FBS. A human breast adenocarcinama MCF-7 (ATCC HTB-22), a human lung cancer cell line EY (gift of Ms Ou Jing), and a mouse pituitary tumor cell line AtT20(ATCC CCL-89) were maintained in Dulbecco's modified Eagle's medium, low glucose (Life Technologies, Inc.) with 10% FBS. Culture media were supplemented with standard antibiotics, and cells were passaged twice weekly.
Rapid Amplificaton of 5Ј-cDNA End (5Ј-RACE) and 5Ј-RACE Product Cloning-The 5Ј-RACE took advantage of tobacco acid pyrophosphatase which was able to remove the "cap" structure from the 5Ј-terminus of eukaryotic mRNA (24, 25) . In our study, JEG-3 or U-2 OS total RNA was first dephosphorylated with calf intestinal alkaline phosphatase (Life Technologies Inc.) to prevent degraded RNA from subsequent ligation with ribo-oligonucleotide, and then tobacco acid pyrophosphatase (Epicentre) was added to dacap the intact mRNA, leaving a phosphorous group suitable for ligation. About 5 g of decapped RNA were later ligated at 20°C for 16 h with T4 RNA ligase (Epicentre) with about 1 g of ribo-oligonucleotide produced by in vitro transcription (Maxiscript Kit, Ambion) (sequence available upon request). One g of ligated product was subject to RT-PCR using HLI-FRSP2 (5Ј-GAACGGGACCTGTTTTCAATGC-3Ј, 444 -423 nt in reported sequence) as the primer for reverse transcription and one primer specific for the ribo-oligonucleotide and one LIFR specific antisense primer LIFR2AS (5Ј-AGGGCGATGAATGAGTCGCAGAGGC-3Ј, 155-131 nt in reported sequence) for PCR. PCR parameters were 94°C, 30 s; 58°C, 30 s; 72°C, 1 min, for 30 cycles. A major band sized of about 160 bp was obtained and cloned into the pCR II vector (Invitrogen). Ten recombinant clones were picked for subsequent sequencing analysis.
Genomic Library Screening-About 1 ϫ 10 6 plaques of a human placental genomic library constructed in FIX II phage vector (Stratagene) were screened with the reported human LIFR (16) cDNA fragment as the probe. Three positive clones were obtained. After restriction mapping analysis and Southern blot with primer LIFRR1S (5Ј-GAACGTGTCTCTGCTGCAAGG-3Ј, 36 -56 nt in reported sequence) as the probe, one clone with an ϳ18-kb insert was found to contain an ϳ4.8-kb sequence upstream of the primer LIFRR15 region. A 7-8-kb NotI-BamHI fragment, which retained this 4.8-kb fragment and an ϳ2-3-kb fragment downstream of the primer LIFRR1S region, was subcloned into the pCRII vector, designated pCRII-NoB, and used for subsequent analysis. S1 Protection Assay-The positive genomic clone containing the 5Ј-upstream region beyond primer LIFRR1S (see Fig. 1 ) was digested by HindIII, and a 325-nt single-stranded DNA probe was produced using standard methods (26) with primer HLIFR2AS. A 5 ϫ 10 5 cpm probe mixed with 0.5 g of JEG-3, U-2, and placental mRNA samples, after hybridizing in hybridization buffer (80% formamide, 100 mM sodium citrate, 300 mM sodium acetate, pH 6.5) at 42°C overnight, 50 units of S1 nuclease (Ambion), was added and incubated at 37°C for 30 min before inactivation of the enzyme. Protected fragments were then precipitated, redissolved, and separated on a 5% polyacrylamide sequencing gel.
Northern Blot Analysis-Total RNA was prepared from JEG-3 and U-2 OS cells using Trizol reagent (Life Technologies, Inc.). Corresponding mRNA was purified from total RNA using a Micro-FastTrack kit (Invitrogen). About 2 g of mRNA derived from different sources were separated on 0.8% agarose-formaldehyde gel and transferred to Hybond N nylon membrane (Amersham Corp.). A 365-bp LIFR cDNA fragment corresponding to the cytoplasmic region was amplified by RT-PCR from human placental mRNA (CLONTECH) with two primers LIFRS and LIFRAS, and was labeled to a specific activity of 1 ϫ 10 9 cpm/g with a random labeling kit (Prime-it II, Stratagene). The membrane was prehybridized in QuikHyb solution (Stratagene) at 65°C for 20 min and hybridized with the probe at 65°C for 1 h. After hybridization, the membrane was washed with 2 ϫ SSC, 0.1% SDS twice at room temperature for 30 min, and then with 0.1 ϫ SSC, 0.1% SDS at 60°C for 30 min.
Construction of Plasmids for Promoter Analysis-A 7-8-kb
NotI/ BamHI fragment in the positive DNA (see Fig. 1 ) was cloned into pCRII at the same restriction site, termed pCRII-NoB, and used for the following subclonings. To analyze the active promoter region of the human LIFR gene, a series of reporter plasmid constructs were made using the backbone of pGL3-Basic vector (Promega), two subclones were obtained first: pGL3-NP contained a 1.2-kb NheI/blunted-PstI DNA fragment from the genomic clone (see Fig. 1 ) inserted at NheI/bluntedHindIII vector site; pGL3-NX contained a 1.5-kb NheI/blunted-XcmI DNA fragment (see Fig. 1 ) including the first exon and first intron inserted at NheI/blunted-HindIII site. To construct the reporter containing the entire Ϫ4.8-kb sequence upstream primer LIFRR1S, a 6.5-kb SalI/EcoRI fragment in pCRII-NoB was subcloned into pBSIISk(ϩ) vector (Stratagene) to make pBSII-SE, then KpnI and NheI were used to recover an ϳ4-kb genomic fragment from pBSII-SE, which contained all the sequence upstream of the NheI site (see Fig. 1 ) in pCRII-NoB, and this 4-kb fragment was cloned into pGL3-NP using KpnI and NheI sites. This new construct thus contained the entire Ϫ4.8-kb sequence upstream of the detected transcription start site and a portion of the first exon and was designated pGL3-KP. Over 30 serial constructs with different deleted sizes using pGL3-KP as a starting template were obtained for promoter activity analysis. Deletions were made using either the exonuclease III and mung bean nuclease method (26) or unique restriction endonuclease sites. All deletions were verified by sequencing.
Construction of Plasmids for Enhancer Analysis-A 1.4-kb KpnISspI fragment (Ϫ4876 to Ϫ3452 nt) from pBSII-SE, containing the strongest transcriptional activation region, was subcloned into pGL3-Basic cut with KpnI and SmaI to make pGL3-KS. Since an XhoI site existed between the KpnI and SalI site in pBSII-SK(ϩ) vector, XhoI digestion on pGL3-KS released the entire 1.4-kb fragment, including the enhancer region. This region was then subcloned into the pGL3-Promoter (Promega) at either the XhoI site or SalI site, allowing the DNA region of interest to be placed upstream or downstream of the luciferase reporter gene in either orientation. These constructs were transfected into different cells for their functional analysis. The construct, designated pGL3PX-(SK) 1 , with the enhancer insert upstream luciferase gene in the opposite orientation, was used further by deletion analysis to localize the minimal enhancer region.
Transient Cell Transfections-For promoter activity analysis, promoterless pGL3-Basic was used as a negative control. For enhancer activity analysis, pGL3-Promoter was used as negative control. Plasmid pCMV-␤-gal (Life Technologies Inc.) was cotransfected as an internal control. Plasmid DNAs were prepared using Maxi-prep Kit (QIAGEN). JEG-3, U-2 OS, JAR, AtT20, MCF-7, EY, Hep3B, HeLa, and TC1 cells were transfected using the standard LipofectAMINE (Life Technologies Inc.) or calcium phosphate precipitation method. Testing plasmid DNA was mixed with pCMV-␤-gal at a 5:1 ratio. Each plasmid sample was co-transfected with pCMV-␤-gal in triplicate, and individual transfections were repeated at least twice. 48 h after transfection, cell lysates were prepared for measurement of luciferase and ␤-gal activities.
Mutagenesis in the Enhancer
Region-Several site-directed mutageneses were performed according to the ExSite PCR method (Stratagene) targeting the Sp1 and NF-B/c-Rel binding sites detected by DNase I footprinting. Only the mutagenic primers are portrayed here. For the Sp1-protected regions 1 (Ϫ4467 to Ϫ4481 nt) and 2 (Ϫ4495 to Ϫ4512 nt), the primers (lowercase represents mutated nucleotides) used were 1a, 5Ј-aagATCATGGCCTGAACTAGTTTTTC-3Ј; 1b, 5Ј-aag-CTTCCCATCATGGCCTGAAC-3Ј; and 2, 5Ј-agaCCTTTTAGAAATAC-TGATAG-3Ј respectively. For the NF-B p50 protected regions 1 (Ϫ4424 to Ϫ4439 nt), 2 (Ϫ4460 to Ϫ4483 nt), and 3 (Ϫ4493 to Ϫ4508 nt), the primers used were 1a, 5Ј-tgCCTTACTGAGAGGATGAGGC-3Ј; 1b, 5Ј-ccggTGCCCTTACTGAGAGGATG-3Ј; 2, 5Ј-gttTTCCCATCATGGCC-TGAACTAG-3Ј; 3, 5Ј-ttcGGTACAATGAGGCATGTCT-3Ј.
For deletion mutant lacking region Ϫ4625 to Ϫ4581 nt, the two primers used were 5Ј-CAATCCCTTATCTTAACCC-3Ј and 5Ј-GCTTCA-GAGAGAATAGATTG-3Ј (the deleted region corresponds to element A); for the deletion mutant lacking region Ϫ4418 to Ϫ4400 nt, the two primers used were 5Ј-CATGGTCAGAAGGTTTAG-3Ј and 5Ј-AGTA-AGGGCATTCCAAAG-3Ј (the deleted region corresponds to element B). All mutants were verified by sequencing.
Preparation of Nuclear Extract and Electrophoretic Mobility Shift Assay (EMSA)-Crude nuclear extract from JEG-3 cells was prepared according to the method of Dignam et al. (27) with modifications. About 1 ϫ 10 8 JEG-3 cells were used, and extraction buffer volumes were scaled down accordingly. The protein concentration of the nuclear extract was quantitated by Bio-Rad protein assay (Bio-Rad) and was usually between 5 and 7 g/l. For electrophoretic mobility shift assay, the oligonucleotide duplex corresponded to element A (Ϫ4625 to Ϫ4581 nt) and element B (Ϫ4418 to Ϫ4400 nt), respectively, in the enhancer region. One strand of the duplex was 5Ј-TGGAGACCAAGGTTTTAT-CATACAGATGAAGCCCCCAGGTAGCA-3Ј for element A, and 5Ј-TTACTGAGAGGATGAGGCCATTCACA-3Ј for element B. Oligonucleotide sequences for Sp1, NF-B, AP1, and cAMP response elementbinding protein were used in the competition assay. The oligonucleotide duplex end-labeled with a [␥-
32 P]ATP, 20,000 -30,000 cpm, probe was mixed with 5-7 g of JEG-3 nuclear protein, 1 g of poly(dI-dC) (Pharmacia) in 20 l of reaction buffer (10 mM Tris-Cl, pH 7.5, 100 mM KCl, 1 mM dithiothreitol, 1 mM EDTA, 8% glycerol) and incubated at room temperature for 15 min. For competition assays, 200-fold excess cold competitor oligonucleotide duplex was added in the reaction buffer 5 min before the addition of the labeled probe. Binding mixtures were resolved on 5% nondenaturing polyacrylamide gel electrophoresis gel.
RESULTS

Mapping the Placental Transcription Start Site of LIFR
Gene-Reported human LIFR cDNA has a length of 3591 nt. However, Gearing et al. (16) , at the time of cloning the human LIFR cDNA, found that the LIFR transcripts in human placental RNA corresponded to two major bands of ϳ6 and ϳ4.5 kb and a minor band of 5 kb. Later reports detected four hybridizing bands using a LIFR probe located within the cDNA cytoplasmic region in placental tissue (28) , although no size estimation was provided. These previous data could not be used to define the transcription start site of this gene. Therefore, to accurately map the transcription start site, 5Ј-RACE and S1 mapping were performed. 5Ј-RACE is useful to capture extra 5Ј sequences lost during conventional cDNA library construction. With LIFRSP2 as the reverse transcription primer and LIFR2AS as the gene-specific primer in the PCR, 5Ј-RACE using tobacco acid pyrophosphatase enzyme and T4 RNA ligase was successful in JEG-3 RNA samples (see Fig. 2a ). However, cloning and sequencing of these 5Ј-RACE products showed discrepancies in the first 11 nucleotides in the largest 5Ј-RACE products as compared with the reported cDNA (Fig. 2b) . Sequence from the 12th nucleotide in the largest 5Ј-RACE product is in agreement with the reported cDNA starting from its 25th nucleotide. Subsequently, we found that RT-PCR using a primer LIFRRPUS (5Ј-AAATCCTAACCCTCTCTCCCAG-3Ј) designed from the beginning of 5Ј-RACE product sequence as sense primer and LIFR2AS or LIFRGD1AS (5Ј-TCCATCATCT-GTGCAATGCAGTC-3Ј, 186 -164 nt in reported sequence) as antisense primer was successful, whereas RT-PCR using a primer designed from the beginning of the previously reported cDNA sequence (corresponding to its 13th to 35th nucleotide) and LIFR2AS or LIFRGD1AS primer was unsuccessful (data not shown), thus demonstrating that the first 11-nt sequence detected by 5Ј-RACE was correct and present in LIFR transcripts in JEG-3 cells.
Plasmid pCRII-NoB was partially sequenced around the primer LIFRR15 site, and a HindIII site (Fig. 1 ) was detected at Ϫ183 of the first nucleotide obtained in the 5Ј-RACE product. For the S1 protection assay, the positive genomic DNA clone was therefore digested with HindIII, and primer LIFR2AS was used to synthesize a single-stranded DNA probe. S1 mapping showed a single protected fragment of 143 nt (Fig.  2c) , which agrees with the transcription start site as determined by 5Ј-RACE. Interestingly, the U-2 OS sample did not yield the corresponding signal, whereas both JEG-3 and placental samples gave strong positive protected signals.
At the same time, partial sequencing of pCRII-NoB plasmid revealed discontinuity of the cDNA sequence at the 159-nt position, indicating the existence of intron(s). This information was later utilized for plasmid constructions in the promoter activity analysis.
Promoter Activity of Human LIFR Gene 5Ј-Flanking Sequence Upstream to the Identified Placental Transcription Start Site-Over 30 serial nested deletion subclones generated from pGL3-KP, which contained the 4.8-kb region upstream of the identified transcription start site and 52 nt of the first exon, were sequence-verified and used for promoter activity assay. The 4876-nt 5Ј-flanking fragment sequence has been deposited 
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TM under accession no. U78104. This 4.8-kb fragment can be divided into five regions as shown in Fig. 3 , according to their contribution to the promoter activity. The minimal promoter was localized within the Ϫ162-nt region designated as region V (Ϫ162 to Ϫ1 nt). No TATA box or GC box was found proximal to the transcription start site, but an initiator element (CTCAAATCCT) was found at Ϫ3 to ϩ7 nt around the transcription start site. This initiator element may be important for the discrete transcription of this gene. Among the four other regions, region I (Ϫ4876 to Ϫ3412 nt), II (Ϫ3411 to Ϫ2572 nt), and IV (Ϫ797 to Ϫ163 nt) increased promoter activity, while region III (Ϫ2571 to Ϫ798 nt) inhibited promoter activity. Inclusion of the complete first exon had no significant influence on promoter activity, as demonstrated by pGL3-NX (Fig. 3) .
Region I is very striking because inclusion of this region can increase promoter activity by a further 8 -12-fold, resulting in overall promoter activity more than 200-fold higher than that of the promoterless control vector. We reasoned that this region might contain an enhancer and used it for further characterization.
Alternative Promoter Usage of the Human LIFR Gene-An osteogenic sarcoma cell, U-2 OS, exhibiting high level LIF expression (29) , was also chosen for thorough analysis alongside the JEG-3 cells. In a Northern analysis, when using a 365-bp LIFR cDNA fragment probe corresponding to the LIFR cytoplasmic region, similar levels of LIFR transcripts were detected in both JEG-3 and U-2 OS samples (Fig. 4a) . However, the 5Ј-RACE of U-2 OS RNA sample using the same antisense primers used for JEG-3 5Ј-RACE was not successful (data not shown), and in an S1 mapping study shown in Fig. 2b , a U-2 OS RNA sample failed to give rise to a protected fragment. Furthermore, transfection of pGL3-KP, pGL3-KP(Ϫ798), or pGL3-KP(Ϫ162) into U-2 OS cells did not induce luciferase reporter activity. These observations implied that U-2 OS cells might utilize an alternative promoter for LIFR transcription.
As previously stated, in the positive genomic clone containing the functional promoter described above, we detected the presence of an intron situated 145 nt behind the transcription start site, so we decided to use this first exon (1-145 nt) present in JEG-3 cells as the probe to rehybridize to the same blot shown in Fig. 4a . The result is shown in Fig. 4b . Not surprising, this unique exon indeed failed to detect a signal in U-2 OS cells, providing further evidence that an alternative promoter is utilized by the LIFR gene in U-2 OS cells.
Since the original primers used in 5Ј-RACE and S1 mapping for JEG-3 and U-2 OS RNA samples are in fact all located within the first exon in LIFR transcripts in JEG-3 cells, novel primers were designed from within the translated region of the LIFR (outside the first LIFR exon in JEG-3 cells) to repeat 5Ј-RACE with the U-2 OS sample, and the new 5Ј-RACE product revealed a different, high GC content fragment of 29 nt at the 5Ј-end (Fig. 5, a and b) . Using a primer derived from this 29-nt sequence, a PCR-based genomic walking was performed, and a 676-bp genomic fragment upstream of the 29-nt sequence was cloned into pGL3-Basic, designated as pGL3-U2P, and found to have promoter activity in U-2 OS cells and other nonplacental cells tested including Hep3B, MCF-7, AtT20 (Fig.  5c) , HeLa, EY, and TC1 cells, but not in JEG-3 (Fig. 5c ) or JAR cells. This 676-bp genomic sequence has been deposited in GenBank TM under accession no. AF018079. Enhancer Activity Analysis and Tissue Specificity of the Promoter and Enhancer-The XhoI fragment (Ϫ4876 to Ϫ3452 nt) in pGL3-KS, which contained the entire region I, was subcloned into pGL3-Promoter vector at different sites or orientation to test for its effect on SV40 promoter activity. Subsequently, this 1.4-kb fragment is referred to as KpnI-SspI (KS) fragment from Ϫ4876 to Ϫ3452 nt (see Fig. 1 ). Eight different subclones were obtained and were designated pGL3PX-(KS) 1 , (KS) 2 , (SK) 1 , and (SK) 2 for insertion at XhoI site upstream the SV40 promoter according to orientation and tandem repeat occurrence, and PGL3PS-(KS) 1 , (KS) 2 , (SK) 1 , and (SK) 2 for insertion at SalI site downstream of the luciferase reporter gene according to the orientation and tandem repeat occurrence. Luciferase activity of these constructs is shown in Fig. 6 . One copy of the 1.4-kb KS fragment, when placed either upstream or downstream to the reporter gene in either orientation, increased promoter activity by 10 -35-fold, with pGL3PX-(SK) 1 (KS fragment placed upstream the SV40 promoter in opposite orientation to luciferase reporter) having the largest induction (35-fold), thus confirming that this 1.4-kb fragment indeed contained an enhancer region. Tandem repeats of the 1.4-kb KS fragment placed at those positions increased promoter activity 24 -74-fold, showing cumulative enhancer activity of this KS fragment.
As a further step to study this newly found functional promoter and enhancer, we transfected pGL3-KP, pGL3-KP(Ϫ798), and pGL3PX-(SK) 2 in comparison with control pGL3-Basic or pGL3-Promoter vectors into two placental cell lines and seven nonplacental cell lines to test the tissue specificity of the promoter and enhancer. Results of two placental and three nonplacental cell transfections are shown in Fig. 7 . As portrayed, this promoter and enhancer were only functional in placental cell lines such as JEG-3 and JAR, while remaining inactive in hepatocarcinoma Hep3B, lung cancer EY, pituitary tumor AtT20 cells, and other cells including sarcoma U-2 OS, cervix carcinoma HeLa, breast cancer MCF-7, and thyroid carcinoma TC1 (data not shown).
Analysis of the Enhancer Region-pGL3PX-(SK) 1 was then used for deletions in the KS fragment insert from both ends to determine the minimal enhancer region. Subclones with about 300 bp intact (Ϫ4705 to Ϫ4400 nt, BstXI to XmnI fragment) retained full enhancer activity, and this 300-bp fragment was used for subsequent studies.
As shown in Fig. 8 , the minimal enhancer can be further localized as a 226-nt fragment from Ϫ4625 to Ϫ4400 nt, and predicted potential transcription factor binding sites for this region are shown in Fig. 9 . Notably, two Sp1 and three NF-B/ c-Rel binding sites with moderate binding strength were predicted. To determine whether these Sp1 or NF-B/c-Rel binding sites are functional in binding corresponding proteins and or contributing to enhancer activity, both DNase I footprinting and site-directed mutagenesis were performed. Although two Sp1 and three NF-B/c-Rel binding sites bound to Sp1 and NF-B p50 correspondingly, only site-directed mutagenesis at one c-Rel site caused about 30% loss of enhancer activity, while other mutants retained full enhancer activity. These results demonstrate that the predicted Sp1 or NF-B/c-Rel binding sites, albeit capable of binding to corresponding transcription factors, do not play major roles in enhancer function.
However, as shown in Fig. 8 , two deletion mutants losing either end of this fragment, namely D2 without the Ϫ4625 to Ϫ4583 nt region and D6 without the Ϫ4453 to Ϫ4400 nt region, were found to be completely inactive, suggesting that Ϫ4625 to Ϫ4583 nt and Ϫ4453 to Ϫ4400 nt are two important regions for enhancer activity. Since one NF-B binding site (Ϫ4439 to Ϫ4424 nt) was within the Ϫ4453-nt to [minus4400 nt region, another deletion mutant was made to retain the NF-B binding site while losing the fragment from Ϫ4418 to Ϫ4400 nt. Transient transfection showed that this new deletion mutant, D7 as shown in Fig. 8 , did not possess enhancer activity. Thus, two elements, A (Ϫ4625 to Ϫ4583 nt) and B (Ϫ4418 to Ϫ4400 nt) have been found to be indispensable for enhancer activity.
Several internal deletion mutants possessing intact ends, but disrupting the integrity of the enhancer fragment, were also found to lose their activity, as shown in Fig. 8 . To test whether specific proteins can bind to these two regions, EMSA was performed using an oligonucleotide duplex corresponding to these two elements as probes, and the results are shown in Fig. 10 . Both elements can give rise to specific protein binding bands, with element A showing two major bands (arrowed) and two minor bands, and element B showing one band (arrowed).
However, several known transcription factor consensus binding sequences could also not compete with the specific bindings, and the two elements could also not compete with each other. Further analysis of elements A and B using nuclear extracts from U-2 OS and HeLa showed that all three arrowed shifted complexes shown in Fig. 10 can also be detected in these two nonplacental sources, implying that the corresponding proteins may not be unique to placental tissue (data not shown). DISCUSSION LIFR is a widely expressed transcript, supporting the observed diverse functions of LIF in different tissues. However, in the human cell lines that we used for transfection studies, RT-PCR using LIFRS and LIFRAS were all able to generate the expected PCR product, while RT-PCR using primer LIFRR1S found in the first exon in JEG-3 cell and a primer downstream ATG initiation codon LIFR1AS (5Ј-CTTTTATT-GTCCACCATCCAG-3Ј, 234 -214 nt in reported sequence) could generate only the expected PCR products in two placental cells, JEG-3 and JAR cells, and in normal placental tissue. Activity of the cloned enhancer (a) and promoter (b) in different cell lines was measured in triplicate transfection assays, and representative results from two placental and three nonplacental cell lines are presented. Luciferase activity was normalized to ␤-gal activity and for each cell line the normalized pGL3-Promoter or pGL3-Basic control readings were set as 1, respectively. pGL3PX-(SK) 2 was used to test for enhancer tissue specificity with pGL3-Promoter as a control; pGL3-KP and pGL3-KP(Ϫ798) were used to test for promoter tissue specificity with pGL3-Basic as a control. 1, pGL3-Promoter; 2, pGL3PX-(SK) 2 ; 3, pGL3-Basic; 4, pGL3-KP(Ϫ798); 5, pGL3-KP. placenta specificity of the characterized promoter and enhancer, whereas the alternative promoter appears to possess broader tissue activity.
Transcription factor Sp1 and NF-B have broad tissue distribution and have been found to be involved in many enhancer elements. For example, Sp1 contributes to the enhancer activity in fibroblast growth factor-4 gene (30), human adenosine deaminase gene (31) , and insulin-like growth factor-II/mannose 6-phosphate receptor gene (32) , while members of the NF-B family transcription factor are necessary for the enhancer activity of 3-Ј IgH enhancer (33), HIV-1 enhancer (34), and CD28RE enhancer in the IL-2 gene (35) . In some cases, both Sp1 and NF-B participate in activating enhancers; constitutively bound Sp1 and induced heterodimeric NF-B give rise to maximal activity of the cytokine-inducible enhancer of vascular cell adhesion molecule-1 gene (36) , and Sp1 and NF-B interact with HIV-1 enhancer activator (37) . Specifically for placental tissue, a Sp1-like element was found to participate in the regulation of several pregnancy-specific glycoprotein (PSG) genes including PSG-3, PSG-5, PSG-6, and PSG-11 (38) .
However, in the LIFR enhancer described here, although the enhancer does contain two Sp1 and three NF-B/c-Rel binding sites (EMSA was also performed with JEG-3 crude extract and specific binding were observed for both Sp1 and NF-B binding sequences, data not shown), these transcription factors do not play major roles in enhancer activity.
Regulatory elements mediating enhanced expression of some placental genes have been reported. For the human chorionic gonadotropin ␣ subunit gene, a composite enhancer was found located within the first 435 bp of the promoter for placentaspecific expression. This enhancer contains upstream regulatory element (URE), two tandem CREs, and CCAAT box (39) , in which URE is actually a composite of ␣ ACT, trophoblastspecific element (TSE), and URE1 (40), among which ␣ ACT can bind to hGATA-2 and hGATA-3 (41), TSE/URE1 can bind to TSEB and UREB. For the human chorionic somatomammotropin gene, a placental-specific enhancer chorionic somatomammotropin, located about 3 kb downstream of the hCS-2 gene, contains multiple DNA elements observed in footprinting with corresponding proteins including TEF-1 interacting cooperatively (42) , and more recently, human transcription factor TEF-5 has been shown to be important to regulate the hCS-B gene enhancer (43) . Also, CRE, GATA, basic helix loop helix, and TSE have been found indispensable for the function of a 770-bp enhancer located Ϫ5.4 kb upstream of the murine adenosine deaminase gene in trophoblast cells of chorioallantoic placenta (44) . As shown in Fig. 7 , potential transcription factor binding sites in this LIFR enhancer region include CRE, GATA, HNF-3, Nkx25, Sp1, NF-B, Oct-1, NF-1, E47, and Delta EF-1. Of these transcription factors, CRE and GATA have been implicated in placental-specific regulation mentioned above. No TSE motif was found. We have not yet made a more detailed analysis targeting these potential binding sites. Nevertheless, two novel elements A (Ϫ4625 to Ϫ4583 nt) and B (Ϫ4418 to Ϫ4400 nt) are found to be indispensable to LIFR enhancer activity. Data base searching could not correlate these two elements to known transcription factor binding sites, but these two elements demonstrated specific binding with nuclear proteins derived from JEG-3 cells, with element A showing two major specific bands and two minor bands in EMSA and element B showing one specific band in EMSA. Competition assay using four known consensus binding sequences for Sp1, AP1, NF-B, and cAMP response elementbinding protein confirmed their binding specificity. Furthermore, elements A and B could not compete with each other, showing that they are binding to different proteins. Those two major shifted complexes for element A and one shifted complex for element B have also been found to be detectable in U-2 and HeLa nuclear extracts (data not shown), implying that those corresponding proteins may not be unique to placenta. Considering that deletion of either element A or element B resulted in the total loss of enhancer activity, and disruption of the enhancer integrity by internal deletion also rendered the enhancer inactive, it is reasonable to conclude that binding proteins in this enhancer region do not contribute to enhancer activity separately. Rather, they probably cooperate with each other or with co-factors and allow the protein-protein interaction to permit enhancer activity.
On the other hand, in this 226-bp enhancer region there is another 162 bp between element A and element B, in which two Sp1 and three NF-B/c-Rel binding sites mentioned above were located. Although those Sp1 or NF-B/c-Rel binding sites do not contribute to enhancer activity, internal deletion in this region disrupted the enhancer activity, possibly other transcription factor binding sites in this 162-bp region are necessary for enhancer activity.
Interestingly, transfections have shown that this enhancer could also be placental specific because when placed upstream of an SV40 promoter, this enhancer was not active in several nonplacental cell lines tested including breast cancer, pituitary tumor, osteogenic sarcoma, cervix carcinoma, liver carcinoma, lung cancer, and thyroid carcinoma. The presence of functional placental-specific transcription factor(s) binding to this enhancer region will be a good hypothesis to explain the placental enhancer specificity.
LIFR knockout mice have severe defects in placental organization (22) , showing the importance of LIFR in normal placental development. In mice, mLIFR mRNA expression level was shown to increase in placenta during pregnancy (45) . In humans, LIFR mRNA also increases during the first trimester in placenta (46) . No explanation has yet been provided for these LIFR mRNA increases being restricted to placenta and or during pregnancy. With the discovery of functional placenta-specific LIFR enhancer described here, we hypothesize that in placenta and/or during pregnancy, placenta-specific transcription factor(s) are active and able to bind to the placenta-specific LIFR promoter and enhancer, leading to increased transcription of LIFR mRNA restricted to the placenta. An alternative LIFR gene promoter is active in a wide variety of nonplacental tissues, allowing nonplacental expression of LIFR and also supports the notion that LIFR possesses specific regulatory signals to regulate its expression and special functions in placenta. Cloning of this functional human LIFR promoter and enhancer has provided the basis to study the regulation of LIFR expression, and detailed analysis in the enhancer and promoter region will reveal further mechanisms for their demonstrated tissue specificity.
